ArticleFrontiers in aging neuroscience2025
Diagnostic potential of urinary CX3CL1 for amnestic mild cognitive impairment and Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- CX3CL1 in Early Detection of Alzheimer's Disease: Plasma Dynamics Across Age and Disease Stages.Annals of clinical and translational neurology · 2026Article
- Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.Alzheimer's research & therapy · 2026Article
- Insights into Biomarkers of Alzheimer's Disease: From Core Markers to Emerging Directions.Aging and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The role of the chemokine CX3CL1 in the processes of aging and Alzheimer's disease (AD) pathogenesis is well-established. This study aims to evaluate the diagnostic potential of urinary CX3CL1 levels in distinguishing between AD patients, those experiencing amnestic mild cognitive impairment (aMCI), and cognitively normal (CN) individuals. Methods: A cohort comprising 516 CN individuals across various age groups, 102 AD patients, and 65 subjects with aMCI was assembled, alongside 93 age- and sex-matched CN controls. Enzyme-linked immunosorbent assay (ELISA) was utilized to quantify urinary CX3CL1 levels. Results: Urinary CX3CL1 concentrations exhibited an age-dependent increase and demonstrated a positive correlation with age. Comparatively, AD patients exhibited significantly elevated urinary CX3CL1 levels when contrasted with both the CN controls and the aMCI cohort. Conversely, aMCI patients displayed urinary CX3CL1 levels that were notably reduced in comparison to both the AD and CN groups. Conclusion: Urinary CX3CL1 levels correlate with the aging process and may serve as a potential diagnostic biomarker for both amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.